Abstract
Adverse drug effects on the immune system function represent a significant concern in the pharmaceutical industry, because 10–20% of the drug withdrawal from the market is accounted to immunotoxicity. Immunosuppression is one such adverse effect. The traditional immune function test used to estimate materials’ immunosuppression is a T-cell-dependent antibody response (TDAR). This method involves a 28 day in vivo study evaluating the animal’s antibody titer to a known antigen (KLH) with and without challenge. Due to the limited quantities of novel drug candidates, an in vitro method called human leukocyte activation (HuLa) assay has been developed to substitute the traditional TDAR assay during early preclinical development. In this test, leukocytes isolated from healthy donors vaccinated with the current year’s flu vaccine are incubated with Fluzone in the presence or absence of a test material. The antigen-specific leukocyte proliferation is then measured by ELISA analyzing incorporation of BrdU into DNA of the proliferating cells. Here, we describe the experimental procedures for investigating immunosuppressive properties of nanoparticles by both TDAR and HuLa assays, discuss the in vitro–in vivo correlation of these methods, and show a case study using the iron oxide nanoparticle formulation, Feraheme.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss RM (2007) Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 6(11):904–916. doi:10.1038/nrd2423
Smith DA, Schmid EF (2006) Drug withdrawals and the lessons within. Curr Opin Drug Discov Devel 9(1):38–46
Wysowski DK, Nourjah P (2004) Analyzing prescription drugs as causes of death on death certificates. Public Health Rep 119(6):520. doi:10.1016/j.phr.2004.09.001
Wysowski DK, Swartz L (2005) Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 165(12):1363–1369. doi:10.1001/archinte.165.12.1363
Tyner K, Sadrieh N (2011) Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review. Methods Mol Biol 697:17–31. doi:10.1007/978-1-60327-198-1_3
Tyner KM, Zou P, Yang X, Zhang H, Cruz CN, Lee SL (2015) Product quality for nanomaterials: current U.S. experience and perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 7(5):640–654. doi:10.1002/wnan.1338
Bancos S, Tyner K, Weaver JL (2013) Immunotoxicity testing for drug–nanoparticle conjugates: regulatory considerations. In: Dobrovolskaia MA, SE MN (eds) Handbook of immunological properties of engineered nanomaterials. World Scientific Publishing, Singapore
Dobrovolskaia MA, Germolec DR, Weaver JL (2009) Evaluation of nanoparticle immunotoxicity. Nat Nanotechnol 4(7):411–414. doi:10.1038/nnano.2009.175
Collinge M, Cole SH, Schneider PA, Donovan CB, Kamperschroer C, Kawabata TT (2010) Human lymphocyte activation assay: an in vitro method for predictive immunotoxicity testing. J Immunotoxicol 7(4):357–366. doi:10.3109/1547691x.2010.523881
Shen CC, Liang HJ, Wang CC, Liao MH, Jan TR (2011) A role of cellular glutathione in the differential effects of iron oxide nanoparticles on antigen-specific T cell cytokine expression. Int J Nanomedicine 6:2791–2798. doi:10.2147/ijn.s25588
Shen CC, Liang HJ, Wang CC, Liao MH, Jan TR (2012) Iron oxide nanoparticles suppressed T helper 1 cell-mediated immunity in a murine model of delayed-type hypersensitivity. Int J Nanomedicine 7:2729–2737. doi:10.2147/ijn.s31054
Shen CC, Wang CC, Liao MH, Jan TR (2011) A single exposure to iron oxide nanoparticles attenuates antigen-specific antibody production and T-cell reactivity in ovalbumin-sensitized BALB/c mice. Int J Nanomedicine 6:1229–1235. doi:10.2147/ijn.s21019
Dobrovolskaia MA, McNeil SE (2013) Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release 172(2):456–466. doi:10.1016/j.jconrel.2013.05.025
Acknowledgment
This project has been funded in whole or in part by federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Potter, T.M., Neun, B.W., Dobrovolskaia, M.A. (2018). Methods for Analysis of Nanoparticle Immunosuppressive Properties In Vitro and In Vivo. In: McNeil, S. (eds) Characterization of Nanoparticles Intended for Drug Delivery. Methods in Molecular Biology, vol 1682. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7352-1_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7352-1_14
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7350-7
Online ISBN: 978-1-4939-7352-1
eBook Packages: Springer Protocols